ACC/AHA Guideline Recommendations Following Acute Coronary Syndrome: A Key to Their Hearts Educational Activity

Title:

ACC/AHA Guideline Recommendations Following Acute Coronary Syndrome: A Key to Their Hearts Educational Activity
Topic: Cardiology
Relevant Terms: Acute Coronary Syndrome, Coronary Artery Disease, Myocardial Infarction, Percutaneous Coronary Intervention
Primary Audience: Primary Care Clinicians; Family Practitioners; Internists; and other healthcare professionals interested in the management of patients with ACS
Launch Date: 22-Dec-10
Credits: 0.75 AMA PRA Category 1 Credit™
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: The Key to Their Hearts 2.0: Management of Patients Following Acute Coronary Syndrome

Learning Objectives

Upon completion of the activity, participants should be able to:

  1. Ensure that patients are started on and remain adherent with statin, β-blocker, inhibitors of the renin-angiotensin-aldosterone axis, aspirin, and thienopyridine therapy in the setting of post-ACS according to ACC/AHA/SCAI guidelines to reduce risk for reinfarction and mortality

    Faculty

    Christopher P. Cannon, MD
    Senior Investigator, TIMI Study Group
    Associate Physician
    Cardiovascular Division, Brigham and Women's Hospital
    Associate Professor of Medicine, Harvard Medical School
    Boston, Massachusetts     Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FAHA, FCCP, FACC
    Director of Preventive Cardiology
    Sterling Rock Falls Clinic, Ltd.
    Sterling, Illinois
    Clinical Professor
    University of Illinois School of Medicine
    Peoria, Illinois
    Physician Continuing Medical Education
    Accreditation Statement
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ACCELMED. PIM is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
     
    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    Dr. Cannon serves on the advisory board (funds donated to charity) for: Bristol-Myers Squibb/sanofi-aventis Partnership; and Novartis International AG. He is a clinical advisor and holds equity in Automedics Medical Systems. He conducts contracted research for: Accumetrics, Inc.; AstraZeneca; GlaxoSmithKline; Intekrin Therapeutics, Inc.; Merck & Co., Inc.; and Takeda Pharmaceuticals North America, Inc.

    Dr. Toth serves on the speakers' bureaus for Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Genentech; GlaxoSmithKline; Merck & Co., Inc.; Pfizer Inc.; and Takeda Pharmaceuticals North America, Inc. He receives consultant fees from Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Genentech; and Merck & Co., Inc. He is on the advisory boards for AstraZeneca; Lilly USA, LLC; and Merck & Co., Inc.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
     
    The following ACCELMED planners and managers Stephanie Breslan, MS, hereby states that she has no relationships with commercial interests, and Janardhan Sampath, PhD, is married to an employee of Lilly USA, LLC.
     
    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period December 22, 2010 through December 22, 2011 participants must read the learning objectives and faculty disclosures and study the educational activity. 
     
    PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation following the activity. Upon registering and successfully completing the post-test with a score of 80% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
     
    Media
    Internet

    Estimate Time to Complete
    0.75 hrs
     
    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), ACCELMED, Daiichi Sankyo, Inc., Lilly USA, LLC, and RealCME do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ACCELMED, Daiichi Sankyo, Inc., Lilly USA, LLC, and RealCME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
      
    Acknowledgement


    This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.